- Conditions
- Gastrointestinal Disease, Esophageal Cancer
- Interventions
- PET/CT (FDG PET/CT), Biomarker Testings
- Procedure · Other
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 31 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2015
- U.S. locations
- 1
- States / cities
- Houston, Texas
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 24
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Fabry Disease, Healthy
- Interventions
- Not listed
- Lead sponsor
- National Institute of Neurological Disorders and Stroke (NINDS)
- NIH
- Eligibility
- Male only
- Enrollment
- 24 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2000 – 2001
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Melanoma, Melanoma Stage III, Melanoma Stage IV, Unresectable Melanoma
- Interventions
- 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography
- Diagnostic Test
- Lead sponsor
- University of Wisconsin, Madison
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2029
- U.S. locations
- 1
- States / cities
- Madison, Wisconsin
- Conditions
- Malignant Neoplasm
- Interventions
- aldesleukin, fludarabine phosphate, cyclophosphamide, laboratory biomarker analysis, NY-ESO-1 reactive TCR retroviral vector transduced autologous PBL, dendritic cell vaccine therapy, fludeoxyglucose F 18, positron emission tomography
- Biological · Drug · Other + 2 more
- Lead sponsor
- Jonsson Comprehensive Cancer Center
- Other
- Eligibility
- 16 Years and older
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2027
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Cancer
- Interventions
- Bone scan, 99mTc-methyl diphosphonate, Positron Emission Tomography (PET) scan, 18F-Fludeoxyglucose (18F-FDG), Computed Tomography (CT) scan, 18F-Sodium Fluoride (18F-NaF), Whole Body Magnetic Resonance Imaging (WB-MRI) scan, Gadopentetate dimeglumine, Gadofosveset, Gadobutrol
- Procedure · Drug
- Lead sponsor
- Stanford University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 114 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2019
- U.S. locations
- 1
- States / cities
- Stanford, California
- Conditions
- Lymphoma
- Interventions
- Bleomycin Sulfate, Doxorubicin Hydrochloride, Procarbazine Hydrochloride, Vinblastine Sulfate, Dacarbazine, Cyclophosphamide, Etoposide phosphate, prednisone, Radiation Therapy, Fludeoxyglucose F-18, computed tomography, Positron Emission Tomography
- Biological · Drug · Radiation + 1 more
- Lead sponsor
- Alliance for Clinical Trials in Oncology
- Other
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 164 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2018
- U.S. locations
- 95
- States / cities
- Tucson, Arizona • Duarte, California • New Haven, Connecticut + 72 more
- Conditions
- Mild Cognitive Impairment
- Interventions
- [11C]Acetoacetate[18F]Fluorodeoxyglucose positron emission tomography scan
- Other
- Lead sponsor
- Wake Forest University Health Sciences
- Other
- Eligibility
- 50 Years to 85 Years
- Enrollment
- 42 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015 – 2024
- U.S. locations
- 1
- States / cities
- Winston-Salem, North Carolina
- Conditions
- Lymphoma
- Interventions
- filgrastim, rituximab, carboplatin, cyclophosphamide, doxorubicin hydrochloride, etoposide, ifosfamide, prednisone, vincristine
- Biological · Drug
- Lead sponsor
- Eastern Cooperative Oncology Group
- Network
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2019
- U.S. locations
- 104
- States / cities
- Palo Alto, California • Fort Collins, Colorado • Jacksonville, Florida + 69 more
- Conditions
- Renal Cell Carcinoma
- Interventions
- FDG PET/MR
- Procedure
- Lead sponsor
- UNC Lineberger Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2019
- U.S. locations
- 1
- States / cities
- Chapel Hill, North Carolina
- Conditions
- PET/CT Imaging
- Interventions
- PET/CT scan with 13 mCi radiation dose, PET/CT scan with 5 mCi radiation dose, PET/CT scan with 2.5 mCi radiation dose, PET/CT Scan with 6.5 mCi radiation dose, PET/CT Scan with not yet determined radiation dose
- Diagnostic Test
- Lead sponsor
- University of Cincinnati
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 190 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2024
- U.S. locations
- 1
- States / cities
- Columbus, Ohio
- Conditions
- Metastatic Sarcoma, Recurrent Sarcoma, Sarcoma
- Interventions
- Computed Tomography, Gallium Ga 68 FAPi-46, Positron Emission Tomography, 18F-FDG
- Procedure · Drug · Radiation
- Lead sponsor
- Jonsson Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2027
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Prostatic Neoplasms, Prostatic Neoplasms, Castration-Resistant, Metastatic Prostate Cancer, Male Urogenital Diseases, Prostatic Diseases, Urogenital Diseases, Male, Genital Diseases, Male, Neoplasms, Neoplasms by Site, Urogenital Neoplasms, Genital Neoplasms, Male
- Interventions
- 18F-Fluciclovine PET/CT Scan
- Drug
- Lead sponsor
- VA Greater Los Angeles Healthcare System
- Federal
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Head and Neck Cancers, Lung and Esophagus Cancers, Anal, Cervix, Vulvar, Vaginal, and Endometrium Cancers
- Interventions
- PET-CT
- Other
- Lead sponsor
- Duke University
- Other
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 271 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2016
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Adenocarcinoma of the Esophagus, Adenocarcinomas of the Gastroesophageal Junction, Recurrent Esophageal Cancer, Squamous Cell Carcinoma of the Esophagus, Stage IV Esophageal Cancer
- Interventions
- pralatrexate, docetaxel, fludeoxyglucose F 18, positron emission tomography
- Drug · Radiation · Procedure
- Lead sponsor
- Ohio State University Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2010
- U.S. locations
- 1
- States / cities
- Columbus, Ohio
- Conditions
- Salivary Gland Squamous Cell Carcinoma, Stage II Salivary Gland Cancer, Stage II Squamous Cell Carcinoma of the Hypopharynx, Stage II Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage II Squamous Cell Carcinoma of the Oropharynx, Stage II Verrucous Carcinoma of the Oral Cavity, Stage III Salivary Gland Cancer, Stage III Squamous Cell Carcinoma of the Hypopharynx, Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage III Squamous Cell Carcinoma of the Oropharynx, Stage III Verrucous Carcinoma of the Oral Cavity, Stage IV Salivary Gland Cancer, Stage IV Squamous Cell Carcinoma of the Hypopharynx, Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage IV Squamous Cell Carcinoma of the Oropharynx, Stage IV Verrucous Carcinoma of the Oral Cavity
- Interventions
- intensity-modulated radiation therapy, cisplatin, image-guided adaptive radiation therapy, 3'-deoxy-3'-[18F]fluorothymidine, positron emission tomography/computed tomography, fludeoxyglucose F 18
- Radiation · Drug · Other + 1 more
- Lead sponsor
- Virginia Commonwealth University
- Other
- Eligibility
- 19 Years and older
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2016
- U.S. locations
- 1
- States / cities
- Richmond, Virginia
- Conditions
- Lung Neoplasm, Lymphoma, Melanoma, Fluorodeoxyglucose, Positron-emission Tomography
- Interventions
- uEXPLORER/mCT, mCT/uEXPLORER
- Device
- Lead sponsor
- University of California, Davis
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 180 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2026
- U.S. locations
- 1
- States / cities
- Sacramento, California
- Conditions
- Recurrent Colon Cancer, Recurrent Rectal Cancer, Stage IIA Colon Cancer, Stage IIA Rectal Cancer, Stage IIB Colon Cancer, Stage IIB Rectal Cancer, Stage IIC Colon Cancer, Stage IIC Rectal Cancer, Stage IIIA Colon Cancer, Stage IIIA Rectal Cancer, Stage IIIB Colon Cancer, Stage IIIB Rectal Cancer, Stage IIIC Colon Cancer, Stage IIIC Rectal Cancer, Stage IVA Colon Cancer, Stage IVA Rectal Cancer, Stage IVB Colon Cancer, Stage IVB Rectal Cancer
- Interventions
- positron emission tomography, computed tomography, magnetic resonance imaging, fludeoxyglucose F 18
- Procedure · Radiation
- Lead sponsor
- Case Comprehensive Cancer Center
- Other
- Eligibility
- 22 Years and older
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2014
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
- Conditions
- Recurrent Adult Soft Tissue Sarcoma, Stage I Adult Soft Tissue Sarcoma, Stage II Adult Soft Tissue Sarcoma, Stage III Adult Soft Tissue Sarcoma, Stage IV Adult Soft Tissue Sarcoma
- Interventions
- fludeoxyglucose F 18, 18F-fluoromisonidazole, positron emission tomography, computed tomography, laboratory biomarker analysis
- Radiation · Other · Procedure
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2013
- U.S. locations
- 2
- States / cities
- Seattle, Washington
- Conditions
- Recurrent Ovarian Epithelial Cancer, Recurrent Ovarian Germ Cell Tumor, Malignant Tumor of Peritoneum, Stage IV Ovarian Epithelial Cancer, Stage IV Ovarian Germ Cell Tumor
- Interventions
- stereotactic body radiation therapy, positron emission tomography, computed tomography, questionnaire administration, fludeoxyglucose F 18
- Radiation · Procedure · Other + 1 more
- Lead sponsor
- Stanford University
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012
- U.S. locations
- 1
- States / cities
- Stanford, California
- Conditions
- Non-alcoholic Fatty Liver Disease (NAFLD), Non-alcoholic Steatohepatitis (NASH)
- Interventions
- Fluorodeoxyglucose (FDG) positron emission tomography (PET), Magnetic resonance imaging (MRI), PET Explorer
- Radiation · Other
- Lead sponsor
- University of California, Davis
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2026
- U.S. locations
- 1
- States / cities
- Sacramento, California
- Conditions
- Recurrent Cervical Cancer, Recurrent Vaginal Cancer, Stage IB Cervical Cancer, Stage II Vaginal Cancer, Stage IIA Cervical Cancer, Stage IIB Cervical Cancer, Stage III Cervical Cancer, Stage III Vaginal Cancer, Stage IVA Cervical Cancer, Stage IVA Vaginal Cancer, Stage IVB Cervical Cancer, Stage IVB Vaginal Cancer, Therapy-related Toxicity
- Interventions
- triapine, cisplatin, external beam radiation therapy, quality-of-life assessment, questionnaire administration, fludeoxyglucose F 18, positron emission tomography, computed tomography
- Drug · Radiation · Procedure + 1 more
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2012
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
- Conditions
- Cervical Adenocarcinoma, Cervical Adenosquamous Cell Carcinoma, Cervical Small Cell Carcinoma, Cervical Squamous Cell Carcinoma, Endometrial Clear Cell Carcinoma, Endometrial Papillary Serous Carcinoma, Stage I Endometrial Carcinoma, Stage IB Cervical Cancer, Stage II Endometrial Carcinoma, Stage IIA Cervical Cancer, Stage IIB Cervical Cancer, Stage III Cervical Cancer, Stage III Endometrial Carcinoma, Stage IVA Cervical Cancer
- Interventions
- fludeoxyglucose F 18, positron emission tomography, computed tomography, ferumoxtran-10, magnetic resonance imaging, diagnostic lymphadenectomy, lymph node biopsy
- Radiation · Procedure · Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 384 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2016
- U.S. locations
- 24
- States / cities
- Los Angeles, California • Sylmar, California • New Britain, Connecticut + 18 more
- Conditions
- Melanoma, Renal Cell Carcinoma (RCC), Non-small Cell Lung Cancer (NSCLC)
- Interventions
- PET/CT imaging with [18F] 2-deoxy-2-(18F)fluoro-D-glucose (FDG)
- Radiation
- Lead sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2018
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Mild Cognitive Impairment, Alzheimer's Disease
- Interventions
- FDG-PET, ASL-MRI, Lumbar Puncture
- Drug · Other · Procedure
- Lead sponsor
- University of Pennsylvania
- Other
- Eligibility
- 55 Years to 89 Years
- Enrollment
- 102 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012 – 2018
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania